Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (787)	3/15/2004 4:54:30 PM
From: Icebrg	Read Replies (2) \| Respond to of 2240

MDX-1307 A new IND pops out of the 10K filed today. No PR has been issued for this agent (as far as I know). MDX-1307 Cancer Phase I Medarex * An IND filing to commence a Phase I clinical trial was accepted by the FDA in February 2004. * We are in the process of a possible public offering of a portion of the common stock of our wholly-owned subsidiary Celldex Therapeutics, Inc. As part of this transaction, we intend to assign our rights to this product, including the associated IND, to Celldex. In such event, we will not be entitled to license fees or milestone payments with respect to this product. We may be entitled to receive royalty payments on any product sales. MDX-1307 (Anti-Mannose Receptor/hCG-ß Antibody)—Colorectal, Pancreatic and/or Bladder Cancers. MDX-1307 is a fusion protein composed of a mannose receptor-specific human antibody conjugated to the beta chain of human chorionic gonadotropin, or hCG. The vaccine is designed to induce antibody and cytotoxic T cell responses directed at cancer cells in patients with ßhCG-expressing tumors. In February 2004, the FDA accepted our IND application to initiate a dose-escalation, multi-dose Phase I study which is expected to enroll up to 18 patients with metastatic or locally advanced colorectal, pancreatic or bladder cancers.